Half of Alnylam Pharmaceuticals' $6 billion market value evaporated Thursday after patient deaths ended a drug trial.
CNBC's Meg Tirrell reports the latest on Gilead. Geoff Porges, Leerink Partners managing director and senior biotech analyst, weighs in.
The dogs of the dow surge. So what's next? With CNBC's Melissa Lee and the Options Action traders.
RSV — or respiratory syncytial virus — has been a problem that's thwarted medicine for more than half a century.
Aside from the financial crisis, health care hasn't lagged the broader market this badly since Bill Clinton was president.
Stocks traded mixed as investors digested remarks made by Federal Reserve Chair Janet Yellen and Vice Chairman Stanley Fischer.
Mylan has raised the price of EpiPens more than 400 percent in recent years. The medicine inside costs $1.
CNBC Pro used Symmetric.io, a tracking research firm, to find the top health care stocks owned by hedge funds with the best health-care stock-picking records.
Biotech stocks have underperformed the market but that could change as investors bet more deals could be in the making.
Pfizer is in advanced talks to acquire Medivation for close to $14 billion, as it seeks to boost its oncology portfolio.
Medivation briefly popped Wednesday after reports that at least five pharmaceutical companies expressed interest in buying it.
Stock buybacks aren't juicing share prices the way they once did, so it pays to be selective, according to UBS.
U.S. equities close slightly lower, despite a rise in oil prices, as investors awaited key retail sales data due later this week.
Shares of Bristol-Myers Squibb briefly fell more than 17 percent in opening trade Friday after its cancer drug failed to meet targets in a late-stage study.
$21 billion is how much investors wiped off the firm after its trial to broaden the use of one of its most promising drugs failed.
Shares of Bristol-Myers Squibb drop on a failed drug trial. Damien Conover, Morningstar equity analyst, discusses his views on the future Bristol-Myers.
Shares of Bristol Myers Squibb are way down today while shares of Merck are up. Here's why, and what's next, with Tony Butler, Guggenheim Securities.
While Bristol Myers Squibb is having its worst day in nearly 16 years, shares of Merck is up 5 percent year over year. Nancy Tengler, Heartland Financial, discusses one of her largest holdings.
Bristol Myers Squibb is having its worst day in nearly 16 years after failing to meet goals for a lung cancer drug. Alex Arfaei, BMO, discusses.
CNBC's Meg Tirrell reports why Bristol-Myers shares are dropping while Merck shares are soaring. The “Fast Money Halftime Report” traders; Stephanie Link, TIAA Global Asset Management; and John Spallanzani, GFI Group chief macro strategist, discuss their views on buying Bristol-Myers on the dip.